656 related articles for article (PubMed ID: 32361569)
1. Breast cancer: Biology, biomarkers, and treatments.
Barzaman K; Karami J; Zarei Z; Hosseinzadeh A; Kazemi MH; Moradi-Kalbolandi S; Safari E; Farahmand L
Int Immunopharmacol; 2020 Jul; 84():106535. PubMed ID: 32361569
[TBL] [Abstract][Full Text] [Related]
2. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
Pavlopoulou A; Oktay Y; Vougas K; Louka M; Vorgias CE; Georgakilas AG
Cancer Lett; 2016 Oct; 380(2):485-493. PubMed ID: 27450721
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A; Ferrari P; Duffy MJ
Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
[TBL] [Abstract][Full Text] [Related]
4. Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways.
Das PK; Rakib MA; Khanam JA; Pillai S; Islam F
Curr Stem Cell Res Ther; 2019; 14(8):669-682. PubMed ID: 31808385
[TBL] [Abstract][Full Text] [Related]
5. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
[TBL] [Abstract][Full Text] [Related]
6. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
[TBL] [Abstract][Full Text] [Related]
7. Three-Dimensional Manufactured Supports for Breast Cancer Stem Cell Population Characterization.
Polonio-Alcalá E; Rabionet M; Ruiz-Martínez S; Ciurana J; Puig T
Curr Drug Targets; 2019; 20(8):839-851. PubMed ID: 30465500
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular aspects of breast cancer: Targets and therapies.
Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
[TBL] [Abstract][Full Text] [Related]
9. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
10. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
11. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
[TBL] [Abstract][Full Text] [Related]
13. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
[TBL] [Abstract][Full Text] [Related]
14. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
15. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
[TBL] [Abstract][Full Text] [Related]
16. Nanocarrier based approaches for targeting breast cancer stem cells.
Pindiprolu SKSS; Krishnamurthy PT; Chintamaneni PK; Karri VVSR
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):885-898. PubMed ID: 28826237
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
18. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
[TBL] [Abstract][Full Text] [Related]
19. Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.
Singer CF; Filipits M; Jahn SW; Abete L; Jakesz R; Greil R; Bauernhofer T; Kwasny W; Seifert M; Fitzal F; Kastner M; Schmitt M; Moinfar F; Gnant M
Breast; 2019 Aug; 46():101-107. PubMed ID: 31132475
[TBL] [Abstract][Full Text] [Related]
20. Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.
Campos-Parra AD; Mitznahuatl GC; Pedroza-Torres A; Romo RV; Reyes FIP; López-Urrutia E; Pérez-Plasencia C
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28574440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]